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A key pathophysiological process and therapeutic target in the critical early post-injury period of 
traumatic brain injury (TBI) is cell mitochondrial dysfunction; characterised by elevation of brain lactate/
pyruvate (L/P) ratio in the absence of hypoxia. We previously showed that succinate can improve brain 
extracellular chemistry in acute TBI, but it was not clear if this translates to a change in downstream 
energy metabolism. We studied the effect of microdialysis-delivered succinate on brain energy state 
(phosphocreatine/ATP ratio (PCr/ATP)) with 31P MRS at 3T, and tissue NADH/NAD+ redox state using 
microdialysis (L/P ratio) in eight patients with acute major TBI (mean 7 days). Succinate perfusion was 
associated with increased extracellular pyruvate (+26%, p < 0.0001) and decreased L/P ratio (−13%, 
p < 0.0001) in patients overall (baseline-vs-supplementation over time), but no clear-cut change in 31P 
MRS PCr/ATP existed in our cohort (p > 0.4, supplemented-voxel-vs-contralateral voxel). However, the 
percentage decrease in L/P ratio for each patient following succinate perfusion correlated significantly 
with their percentage increase in PCr/ATP ratio (Spearman's rank correlation, r = −0.86, p = 0.024). Our 
findings support the interpretation that L/P ratio is linked to brain energy state, and that succinate may 
support brain energy metabolism in select TBI patients suffering from mitochondrial dysfunction.
Following traumatic brain injury (TBI) a series of damaging pathophysiological processes occur in the brain 
that may lead to death or disability. A key component of these events is brain metabolic failure. This can encom-
pass a range of pathological processes including classical ischaemia (lack of blood supply, which may stem from 
raised intracranial pressure or hypotension), hypoxia and increased tissue diffusion barrier. If this energy failure 
occurs in the setting of normal brain oxygenation and glucose supply it is commonly termed mitochondrial 
dysfunction1,2.
We have recently shown that succinate delivered by microdialysis to the injured brain lowers the lactate/
pyruvate (L/P) ratio, which is understood to reflect an improvement in cellular NADH/NAD+ redox state3,4. We 
suggested that succinate therapy achieves this by supporting mitochondrial TCA cycle function, which in turn 
can improve brain energy metabolism. However, it has not yet been demonstrated empirically that improved L/P 
ratio translates to better cellular energetics and is associated with favourable changes in brain high energy phos-
phates – adenosine triphosphate (ATP) and its high-energy reserve species phosphocreatine (PCr).
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In-vivo 31P Magnetic Resonance Spectroscopy (MRS) allows measurement of these high energy phosphates 
in the living brain. Changes in the ratio PCr/ATP, assessed using 31P MRS, have been noted in various cerebral 
pathologies5–10 but we are the first to report 31P MRS in TBI patients who require sedation, intubation and inva-
sive intracranial monitoring for control of intracranial hypertension, and with measurements of extracellular 
biochemistry.
In this study, we measured the ratio of brain PCr/ATP acutely (within the first 10 days following injury) in 
patients suffering from traumatic brain injury using in-vivo 31P Magnetic Resonance Spectroscopy (31P MRS) 
after microdialysis delivery of succinate to establish if changes in L/P ratio are accompanied by changes in brain 
high energy phosphate metabolism. Brain intracellular pH was also evaluated using 31P MRS; as an indicator of 
core physiology.
Results
Patient demographics. Eight patients suffering from TBI received focal disodium succinate (12 mmol/L) 
perfusion for 24 hours via a frontal microdialysis catheter (Table 1) and a preceding/succeeding baseline period of 
microdialysis with normal CNS perfusion fluid. Of the 8 patients, 7 had in-vivo 31P MRS that yielded spectra with 
acceptable signal-to-noise ratio for analysis. Example scan and spectra are shown in Fig. 1.
Succinate supplementation resulted in an improved (lowered) lactate/pyruvate ratio. 
Comparing the period of baseline perfusion with the period of succinate perfusion, we found results similar to 
those in a subset of our previous cohort (Jalloh et al.3) (Table 2) (Fig. 2). Following succinate supplementation, 
there was a statistically significant (by linear mixed effect model) mean 13% decrease in L/P ratio (p < 0.0001, 
decrease in 6/8 patients and increase in 2/8), caused by a mean 25% increase in pyruvate (p < 0.0001, increase 
in 7/8 patients and decrease in 1/8). There was no statistically significant change in lactate, with mean increase 
6% (p = 0.08, increase in 6/8 patients and decrease in 2/8) or glucose, with mean decrease 5% (p = 0.1, decrease 
in 4/8 patients and increase in 2/8). In patients A, B and H the decrease in L/P ratio was considerable (>26%), 
furthermore two of these patients (B and H) had high baseline L/P ratios of 45.1 and 29 respectively. Brain tissue 
oxygen (PbtO2) data were available for 4 patients, whose levels were all 25 mmHg or above, thus none of these 4 
individuals suffered from brain hypoxia during the study. Three patients did not have PbtO2 monitoring, and one 
patient’s PbtO2 data was not available. More detailed PbtO2, intracranial pressure (ICP) and cerebral perfusion 
pressure (CPP) data can be found in Supplementary Table S2.
Decrease of Lactate/Pyruvate ratio was associated with an increased PCr/γATP ratio. There 
was an inverse relationship between the improvement (lowering) in L/P ratio following succinate supplemen-
tation with the increase in PCr/γATP, comparing the voxel receiving the succinate and its ‘control’ contralateral 
partner voxel that did not receive succinate, when these changes in PCr/ATP and L/P ratio were expressed as 
percentages (Fig. 3a; Spearman's rank correlation, r = −0.86, p = 0.024).
31P MRS revealed no difference in PCr/γATP ratio or intracellular pH in cohort overall. The 
frontal voxels supplemented with succinate by their microdialysis catheters were compared with their adjacent 
contralateral equivalent frontal voxels that did not receive succinate supplementation (‘partner’ voxel). We could 
not detect a statistically significant overall difference in PCr/γATP ratio (Fig. 4) between the voxels that received 
focal succinate perfusion and their contralateral equivalent frontal ‘partner’ voxel (Wilcoxon signed rank test, 
p > 0.5). While the group level did not show an overall significant difference, some of these patients had a mark-
edly higher PCr/γATP levels following succinate supplementation (Table 3). Also, we have demonstrated (see 
Patient Age (years) Sex Injury Mechanism Brain Injury Admission GCS Days from TBI Catheter insertion
A 62 M Presumed assault ASDH, brain contusions 10 7 R-CAD
B 63 F Fall from height ASDH, ICH 7 3 R-T
C 24 F RTC EDH, brain contusions 10 4 R-CAD
D 65 M RTC brain contusions 6 6 L-T
E 51 M RTC EDH, ICH 3 4 R-T
F 42 M Assault DAI, early hypoxia* 8 10 L-CAD
G 29 M Assault EDH, brain contusions 8 5 L-CAD
H 42 F RTC ASDH, brain contusions 3 3 L-T
Table 1. Patient demography. M: male, F: female, RTC: road traffic collision, GCS: Glasgow Coma Scale, EDH: 
extradural hematoma, ASDH: acute subdural hematoma, ICH: intracerebral hematoma. GCS denotes highest 
GCS at presentation to emergency services. Catheter insertion denotes side (R/L) and whether via cranial access 
device (CAD) or tunnelled (T) at time of craniotomy/craniectomy. The catheters were not directed into, nor 
adjacent to, lesions identified on computerized tomography (CT). Patients A and C presented only moderately 
drowsy but then rapidly deteriorated; requiring sedation, intubation, ventilation and surgery for their TBI 
followed by a period of intracranial multimodality monitoring and treatment for intracranial hypertension. 
Patients A and F had persistently high ICP and were scanned as soon as they could tolerate lying flat. *Patient 
F had suspected hypoxia at the assault scene, but not while in neurocritical care unit. All patients received 
microdialysis perfusion with succinate and had 31P MRS; in one case (H) the 31P data were unusable due to low 
signal-to-noise.
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above) a statistically significant relationship between percentage increase in PCr/γATP and percentage decrease 
in extracellular L/P ratio (Fig. 3a).
31P MRS revealed no statistically significant difference in brain intracellular pH in the cohort overall as a 
result of succinate supplementation via microdialysis vs. contralateral ‘partner’ voxel without succinate (Wilcoxon 
signed rank test, p = 1). Intracellular pH values are presented in Supplementary Table S1. There was no statisti-
cally significant relationship between percentage change in extracellular L/P ratio and either percentage change 
in brain intracellular pH or absolute change in brain intracellular pH.
Discussion
We demonstrate the first study of human brain metabolism in TBI that combines microdialysis and in-vivo 31P 
MRS – comparing the effect of succinate supplementation on brain metabolism using both modalities.
We have shown that succinate improves NADH/NAD+ redox state (decreases L/P ratio) in the traumatised 
human brain. While we did not detect an overall statistically significant change in high energy phosphates 
(PCr/ATP) after succinate supplementation in the cohort, those individuals who had the greatest improvement 
(decrease) in L/P ratio after succinate perfusion – i.e. those suffering from mitochondrial dysfunction – had con-
siderable increases in their PCr/ATP ratio measured using 31P MRS.
We suggest that the intrinsic heterogeneity of TBI may have been a factor leading to the absence of a clear-cut 
overall difference in PCr/ATP between a succinate-supplemented voxel and its paired contralateral unsup-
plemented voxel when measured simultaneously by 31P MRS in this small cohort of patients. Microdialysis 
Figure 1. Example 31P MRS spectra (a and b) from a patient suffering from acute major TBI, acquired using a 
custom head-coil (Pulseteq Ltd) and 3T Siemens scanner. Axial magnetization-prepared rapid gradient-echo 
(MP-RAGE) MRI scan (c) demonstrates voxel origin within the CSI grid. The patient’s left frontal voxel (yellow 
border, marked ‘Succ’ for succinate, on the right of the image) contains a microdialysis catheter perfused 
with 12 mmol/litre disodium 2,3-13C2 succinate for 24 hours directly before the MR scan (spectrum shown 
in b). The patient’s right frontal voxel (yellow border, marked ‘Ctrl’ for control, on the left of the image) has 
no microdialysis catheter or supplementation and was used as the paired control (spectrum shown in a). Key 
metabolites are annotated. PME: phosphomonoesters, Pi: inorganic phosphate, PDE: phosphodiesters, PCr: 
phosphocreatine, ATP: adenosine triphosphate. For further details see Methods section.
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measurements, contrastingly, were performed within-voxel over a course of time and showed significant differ-
ences across the cohort between an unsupplemented baseline perfusion period and a succinate-supplemented 
perfusion period – notably improvement (lowering) of L/P ratio. Moreover, our finding of a significant correla-
tion within the cohort between percentage decrease in L/P ratio and percentage increase in PCr/ATP suggests 
that succinate supplementation can increase cerebral high-energy phosphate status. This extends previous evi-
dence that succinate delivered by microdialysis is metabolised by the TCA cycle3.
The oxidation of succinate to fumarate is unique as it is both a key step of the TCA cycle and the first step of 
the electron transport chain for the conversion of flavin adenine dinucleotide (FAD) to its reduced form FADH2. 
It is catalysed by succinate dehydrogenase – which is Complex II of the electron transport chain. There is evidence 
that Complex II is less susceptible to injury than Complex I which oxidises nicotinamide adenine dinucleotide 
(NADH), so succinate has been proposed as a substrate that may support the TCA cycle and ATP generation by 
oxidative phosphorylation in stressed cells when mitochondrial function is impaired3,11.
Succinate is unlikely to benefit brain metabolism in cases of hypoxia or ischaemia. Without oxygen, the mito-
chondrial electron transport chain cannot function properly. In experimental ischaemia, succinate dehydroge-
nase (electron transport chain complex II and part of the TCA cycle) was reported to run ‘backwards’, building 
up succinate and reverse electron transport to complex I12. In that study, reperfusion produced a surge in reactive 
oxygen species (via complex I) and cell death. The present study did not involve ischaemia–reperfusion. We 
have previously suggested that using succinate to support mitochondrial metabolism should be performed in the 
presence of adequate oxygenation, not during ischaemia–reperfusion3. None of the four patients in the present 
study with available Licox PbtO2 data suffered from brain tissue hypoxia during the monitoring period, therefore 
we think it unlikely that this affected the other four patients in our study, as they received similar critical care 
management which specifically aims to avoid this. Furthermore, the ISCUS data suggests none of the 8 patients 
studied were ischaemic as microdialysate glucose levels were above 1 mmol/L in each case.
Previously we have shown that 2,3-13C2 succinate delivered via microdialysis enters the TCA cycle of the 
traumatised brain, demonstrated by the detection of downstream 13C labelled metabolites in the collected 
microdialysates using high-resolution 13C NMR3. Succinate uptake into cells can occur via the SLC13 family 
of Na+-coupled di-carboxylate and tri-carboxylate transporters13–15. SLC13 occur widely, including in brain, 
astrocytes and neurons where succinate uptake and metabolism were also shown using radiolabelling16–18. 
Additionally, nonspecific uptake might occur in any cells with increased plasma membrane permeability. 
Appearance of metabolites with characteristic 13C NMR doublet signals clearly indicated uptake and mitochon-
drial metabolism of 2,3-13C2 succinate3. The doubly 13C-labelled metabolites were unambiguous evidence the 
2,3-13C2 succinate molecules crossed from the perfusate into the brain extracellular space, entered the cells and 
were metabolised, exported into the extracellular fluid and recovered by the microdialysis catheter3. In that study, 
succinate potentiated several aspects of brain biochemistry: it significantly lowered extracellular L/P ratio, glu-
tamate and glucose, trended towards elevating pyruvate, but did not significantly change the concentration of 
extracellular lactate3. Based on this, we proposed that succinate increases TCA cycle activity, thereby improving 
brain NADH/NAD+ redox state which aids glucose utilisation leading to increased pyruvate, and draws glutamate 
into the mitochondria to feed the TCA cycle.
The results from the present study support our previous findings and conclusions3 as we again found that 
succinate supplementation reduced extracellular L/P ratio and trended towards reducing brain extracellular glu-
cose levels. We believe that these patients, especially those in which succinate administration was associated 
with greatest decrease in L/P ratio (and in general, had the highest L/P ratio prior to supplementation) are suf-
fering from more pronounced mitochondrial dysfunction, whereas those patients that demonstrate only modest 
changes in L/P ratio may not be so afflicted by disrupted mitochondria, but instead by the other pathophysiolog-
ical processes of TBI. More recent cell culture studies of succinate supplementation to stressed mixed glia show 
Metabolite Condition A B C D E F G H Mean change
L/P ratio
Baseline 16.3 45.1 16.0 20.2 12.5 26.4 18.1 29.0
−13% 
p < 0.0001Succinate 11.5 28.4 14.1 18.4 11.8 26.5 20.6 21.4
% change −29.6 −37.1 −12.1 −8.8 −5.2 +0.6 +14.0 −26.4
Glucose (mM)
Baseline 2.7 1.3 1.9 2.6 3.4 1.5 1.6 1.5
−5% p = 0.1Succinate 3.2 1.1 1.8 1.1 3.7 1.9 1.3 1.7
% change +16.6 +11.3 −6.1 −58.1 +7.4 +23.9 −20.5 +10.3
Lactate (mM)
Baseline 4.0 3.1 1.7 6.3 1.2 6.5 1.6 2.0
+6% p = 0.08Succinate 3.6 3.2 1.8 2.9 1.4 7.1 2.2 2.7
% change −9.9 +2.1 +6.2 −53.4 +13.0 +8.9 +41.6 +36.7
Pyruvate (μM)
Baseline 244 70 105 313 99 247 81 76
+26% 
p < 0.0001Succinate 313 112 133 170 118 268 108 134
% change +28.4 +60.9 +26.4 −45.6 +19.2 +8.1 +33.8 +75.9
Table 2. Results of microdialysis measured by ISCUS for Patients A-H. Mean results of microdialysis samples 
analysed with ISCUS during baseline perfusion with normal perfusion fluid or a period with succinate 
supplemented perfusion fluid. L/P ratio: lactate/pyruvate ratio, mM: millimole/litre, μM: micromole/litre. 
p-values from analysis of pooled results using the package lmer in R, (significance <0.05 denoted by bold font) - 
see Methods subsection Statistical analysis for further details.
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similar findings of increased pyruvate and lowering of tissue L/P ratio after succinate administration in a model 
of mitochondrial dysfunction19. Through increasing TCA cycle activity, glycolysis may also be upregulated which 
would lead to an increase in pyruvate, which commonly occurs in TBI patients20,21.
Another pathway by which succinate may in theory influence brain cells is via interaction with the succi-
nate receptor (SUCNR1, also termed GPR91) which occurs in various tissues and cell types, including micro-
glia, astrocytes and neurons22. SUCNR1 belongs to the G protein-coupled receptors (GPCRs) family, the largest 
group of human proteins involved in signal transduction across biological membranes23. SUCNR1 shows plei-
otropic effects22. Originally an ‘orphan’ receptor with its actual ligand(s) unclear, the succinate-binding capa-
bility of GPR91 was subsequently discovered, although the actual range of ligands, their binding sites and their 
actions are still poorly understood. Due to the complexity of cell signalling, it is (as yet) difficult to categorise 
Figure 2. Line-plots of microdialysis measurements measured by bedside ISCUS: (a) glucose; (b) lactate/
pyruvate ratio (L/P ratio); (c) lactate; (d) pyruvate. Individual subject means from a period of 12 mmol/L 
succinate perfusion (24 hours) and preceding/succeeding baseline perfusion (24 hours) are represented. There 
was a statistically significant 13% (mean of subject means) fall in lactate/pyruvate ratio (p < 0.0001) and a 
statistically significant 26% (mean of subject means) rise in pyruvate (p < 0.0001) analysed using lmer in R. For 
further details see Methods and Results sections.
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SUCNR1 (GPR91) roles. As one example, succinate binding to GPR91 has been reported to enhance post- 
hypoxia-ischaemia vascularization and reduce infarct size in a murine model of new-born hypoxia-ischaemia 
brain injury24.
ATP is the universal molecule of chemical energy in the human body but PCr is only found in tissues that 
require energy in bursts, such as muscle and brain. PCr is considered a temporal ‘buffer’ for ATP in the brain as 
it can donate its phosphate group to ADP via the action of creatine kinase. This rapidly regenerates ATP to allow 
continued cellular processes during periods of demand. PCr also diffuses more readily than ATP so acts as a 
spatial ‘buffer’ for high energy phosphates, shuttling them from where they are generated in the mitochondria 
to where they are used in the cell cytoplasm and cell membrane25. The general perception in phosphorus bio-
chemistry is that when ATP synthesis is running normally, the PCr store is well-stocked; when ATP synthesis is 
struggling to meet demand the PCr store runs down. Absolute quantification of 31P species’ concentrations are 
difficult to achieve accurately with in-vivo 31P MRS, whereas PCr/ATP ratio is readily measurable, facilitating 
inter-comparisons within subjects and between subjects.
We found that succinate supplementation was associated with a considerable increase in PCr/ATP in some 
of our TBI patients, but this did not occur across the group so did not translate to a change in mean PCr/ATP 
overall in our modest-sized cohort. Many different pathophysiological processes contribute to secondary brain 
injury after TBI; including raised intracranial pressure, cerebral hypoperfusion, hypoxia, hypoglycaemia, neu-
roinflammation as well as mitochondrial dysfunction26. Conceivably, those patients whose PCr/ATP ratio was 
less responsive to succinate either suffered from more than one of these complex overlapping pathophysiological 
Figure 3. Bar chart (a) showing the inverse relationship between percentage change in brain microdialysate L/P 
ratio (for succinate perfusion compared with a baseline unsupplemented perfusion period in the same catheter), 
and percentage difference in PCr/γATP (for a voxel that had received succinate perfusion compared to a partner 
control contralateral voxel without succinate). This inverse relationship was statistically significant (Spearman’s 
r = −0.86, p = 0.024). Thus, a greater percentage reduction in the L/P ratio correlates with a greater percentage 
increase in the PCr/γATP ratio. (b) Simplified schematic showing potential mechanism of succinate’s effect on 
PCr/ATP. Succinate misses out Complex I of the mitochondrial electron transport chain. Succinate’s oxidation 
to fumarate by Complex II (succinate dehydrogenase) reduces FAD to FADH2 – which is oxidized back to 
FAD – releasing electrons that pass through a chain of oxidation/reduction reactions, complex II to CoQ, 
complex III, Cytochrome C and complex IV with molecular oxygen as terminal electron acceptor, culminating 
in conversion of oxygen to water, while complexes III and IV export protons across the mitochondrial inner 
membrane creating a proton electrochemical potential gradient, driving ATP synthesis at complex V (ATP 
synthase), converting ADP to ATP. In the mitochondrial intermembrane space ATP donates its high energy 
phosphate to creatine, producing ADP and PCr, which diffuses into the cell cytoplasm for use by cellular 
machinery.
www.nature.com/scientificreports/
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processes, or did not suffer from significant mitochondrial dysfunction, or suffered from mitochondrial dysfunc-
tion refractory to succinate supplementation. In those patients whose mitochondrial dysfunction is responsive 
to succinate, the metabolism of additional succinate to fumarate would generate FADH2, driving ATP generation 
via Complex II. Extra ATP produced (if not used) would be converted to the readily-mobilised store PCr, thereby 
elevating the PCr/ATP ratio (Fig. 3b). Importantly, those patients who did not respond to succinate at least had 
no significant deterioration in their metabolic profile.
An elevated L/P ratio has been shown to be independently associated with poor outcome after TBI27, but 
it is not clear if this is because of brain energy failure. The extracellular L/P ratio is thought to reflect the L/P 
ratio in the cytoplasm – itself in equilibrium with cytoplasmic NADH/NAD+4. Lactate and NADH accumulate 
Figure 4. 31P MRS PCr/γATP boxplot (a) and lineplot (b) of frontal voxels that received microdialysis delivery 
of 12 mmol/L succinate and their corresponding partner (contralateral) frontal voxels that did not receive 
succinate. There were no significant differences in PCr/γATP between succinate supplemented voxels and their 
contralateral voxel without succinate (p > 0.4, paired comparison using Wilcoxon signed rank test). The two 
voxels were analysed within the same MRI scan, in each patient.
Subject I.D.
PCr/γATP ratio Unsupplemented 
(contralateral) voxel
PCr/γATP ratio Succinate-
supplemented voxel
Percentage 
difference
A 0.871 1.528 +75.5%
B 1.089 1.270 +16.6%
C 1.086 1.136 +4.6%
D 1.050 1.082 +3.1%
E 1.134 1.000 −11.9%
F 1.293 1.135 −12.2%
G 0.967 0.963 −0.4%
Table 3. PCr/γATP ratio results from 31P MRS analysis of frontal voxels supplemented with succinate, 
compared simultaneously to their contralateral unsupplemented voxels. 31P MRS measurements of PCr/γATP 
in the frontal voxels of the seven patients who received succinate supplementation. Each voxel that received 
succinate was matched with a partner contralateral frontal voxel that did not receive supplementation, within 
the same patient. The difference in PCr/γATP between supplemented and matched unsupplemented voxels was 
not statistically significantly different (two-tailed Wilcoxon signed rank test p = 0.58). An eight patient (H) also 
underwent 31P MRS but yielded no useable data due to low signal-to-noise.
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when generated by glycolysis; and also by the TCA cycle if the NADH cannot be used by Complex I of the elec-
tron transport chain – the principle mechanism for cellular generation of ATP. The strong association between 
percentage change in L/P ratio and percentage change in PCr/ATP in our small patient group (Spearman’s 
rho = −0.86, p = 0.024) (Fig. 3a) supports the proposal that L/P ratio is linked to downstream energy metabo-
lism, as well as being a representative of NADH/NAD+ redox state. This is the first time that tissue NADH/NAD+ 
redox, as reflected by the extracellular L/P ratio, has been shown to be linked to tissue high energy phosphates 
(PCr and ATP) in the human brain.
The intracellular pH measured by 31P MRS in this study did not correlate with succinate supplementation in 
the group as a whole. As this pH is intracellular, it is possible that these values might not necessarily closely reflect 
the L/P ratio change measured extracellularly. Intracellular pH has been shown by 31P MRS in rat TBI models to 
decrease hyper-acutely following injury, followed by a period of intracellular alkalosis28,29. A 31P MRS study of 
recovering patients in the subacute/chronic phase of TBI found (intracellular) alkalosis of patients’ white matter5. 
The pH changes associated with succinate in Patients A and G could conceivably be indicating a return to more 
normal physiology, but this would need to be corroborated with further study.
We chose to administer succinate through microdialysis catheters because of our experience using this tech-
nique and because it directly delivers succinate focally to the brain – avoiding issues with the blood-brain barrier 
or tissue hypoperfusion seen in the aftermath of TBI. However, the diffusion of succinate from a microdialysis 
catheter may be insufficient to influence the whole of our chosen MRS voxel’s metabolism. Thus, the effect of suc-
cinate will be diluted by the metabolism of unsupplemented tissue within the same voxel. The low gyromagnetic 
ratio of 31P compared to 1H30 meant that we could not decrease our voxel size any further than 2.5 × 2.5 × 2.5 cm3 
whilst maintaining an acceptable signal-to-noise ratio within a practical scan duration (35 minutes). Intravenous 
supplementation of succinate is an alternative delivery method, but needs to be further studied and compared 
with microdialysis brain delivery.
Focal administration of succinate allows direct comparison between a region of succinate supplementation 
and an unsupplemented region in each patient’s brain. However, a caveat to our correlation of L/P ratio and PCr/
ATP is that changes in L/P ratio are related to baseline (unsupplemented) perfusion results from the same region 
of brain, whereas differences in PCr/γATP are relative to an equivalent, paired frontal voxel that did not receive 
supplementation, scanned simultaneously. Due to clinical considerations, an acute-phase ventilated, sedated TBI 
patient is not scanned on consecutive days. It should be noted that the microdialysis pumps were disconnected 
immediately before entering the MR scanner as the pump batteries are non-MR-compliant. As microdialysis 
delivery of substrates occurs relatively slowly, we consider it unlikely the ca. 15-minute interval between pump 
disconnection and 31P MRS acquisition diminished the effect of perfused succinate.
Our pilot study was designed to be able to detect large changes in PCr/γATP after microdialysis delivery of 
succinate to the injured brain. The apparent 10.8% overall rise in PCr/γATP in our cohort did not reach statistical 
significance but might achieve this in future with a larger number of patients. Nevertheless, we have demonstrated 
a significant correlation between changes observed on focal succinate perfusion, namely percentage decrease in 
extracellular L/P ratio and percentage increase in brain (intracellular) PCr/ATP.
Sedation is an important part of patient management in neurocritical care during the acute phase of major 
traumatic brain injury. Sedation’s effects include reduction in cerebral metabolic demand and reduction in intrac-
ranial pressure31. Whereas we did not measure individual patients’ depth of sedation, all were sedated sufficiently 
for endotracheal intubation, mechanical ventilation and control of intracranial hypertension. No changes were 
made to their targeted depth of sedation during the study period. As each patient acted as their own control the 
effects of sedation would be equivalent across all 31P MRS voxels in that individual, and during their baseline and 
supplementation periods of microdialysis perfusion. Variability in time interval between patient injury and scan 
was due to some patients being initially less stable - so that they could not tolerate lying flat any sooner, despite 
optimal medical management. Thus, as all patients still required full sedation, we consider them all to be in the 
‘acute phase’ of TBI, and any difference in brain metabolism due to interval from injury accounted for by each 
patient acting as their own internal control.
Due to the heterogeneity of TBI, it is difficult from the outset to anticipate which patients will suffer from 
mitochondrial dysfunction – the group we postulate will benefit most greatly from succinate supplementation. 
Such individuals can be identified by a combination of multimodality monitoring and advanced scanning tech-
nologies. We propose that a larger study is warranted, including intravenous infusion of succinate to address any 
concerns of limited diffusion from microdialysis catheters, and performing 31P MRS measurement before and 
after succinate perfusion. For reasons mentioned above, an essential prerequisite for employment of succinate is 
the existence of adequate oxygenation and the absence of hypoxia or ischaemia.
In conclusion, we are the first to demonstrate the effect of succinate delivery via microdialysis on the trauma-
tised human brain’s NADH/NAD+ redox state (microdialysate L/P ratio, using an ISCUS bedside analyser) and 
brain high energy phosphate metabolism (PCr/ATP ratio, using 31P MRS of frontal voxels). We found that when 
succinate improved (lowered) brain microdialysate L/P ratio, it was also associated with an increase in brain high 
energy phosphate ratio. This supports the interpretation that L/P ratio is linked to brain energy state, and suggests 
that succinate has potential to support brain energy metabolism in patients who are suffering from mitochondrial 
dysfunction. Further studies of the effects of succinate on brain energy status measured by 31P MRS are required 
using larger patient groups.
Methods
Patient recruitment. We prospectively recruited 8 adults (aged ≥16 years) who had sustained TBI and 
needed intracranial monitoring, sedation, muscular paralysis, intubation and mechanical ventilation. Patients 
were treated in Neuro-intensive care using our standard TBI management protocols32. Targeted depth of seda-
tion was not changed over the study period. Sedation was achieved with propofol, with or without midazolam. 
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Barbiturates were not used. Electroencephalography and bispectral index were not measured as they are not 
routinely used in our unit. Written, informed assent was provided by patients’ relatives, and the study was carried 
out in conformation with the spirit and the letter of the Declaration of Helsinki. The protocol was approved by 
the National Research Ethics Service (NRES) Committee East of England – Cambridge Central (REC Reference 
No. 11/EE/0463).
Microdialysis. Microdialysis monitoring and succinate delivery were carried out as described previously3. 
M Dialysis 71 microdialysis catheters (membrane length 10 mm, nominal molecular weight cut-off 100 kDa) 
(M Dialysis AB, Stockholm, Sweden) were placed via a triple lumen cranial access device (Technicam, Newton 
Abbot, UK) or directly at time of craniotomy/craniectomy into frontal lobe (Table 1). The catheters were not 
directed into, nor adjacent to, lesions identified on computerized tomography (CT), e.g. contusions. Codman 
Microsensor intracranial pressure (ICP) probes (Codman Neuro, Johnson & Johnson, Wokingham, UK) – 
and where available Licox brain tissue oxygen concentration (PbtO2) monitoring probes (Integra LifeSciences 
Corporation, Plainsboro, NJ, USA) – were inserted alongside the microdialysis catheters via the same cranial 
access device. ICP, CPP and PbtO2 was recorded and reviewed with ICM+ software (Cambridge Enterprise 
Ltd., Cambridge, UK)33. Catheters were perfused at 0.3 µL/min with CNS Perfusion Fluid (M Dialysis AB), com-
posed of NaCl (147 mmol/L), KCl (2.7 mmol/L), CaCl2 (1.2 mmol/L) and MgCl2 (0.85 mmol/L) in water, supple-
mented with 12 mmol/L disodium 2,3-13C2 succinate (8 patients; isotopic enrichment 99%, chemical purity 99%) 
(Cambridge Isotope Laboratories, Inc, Tewksbury, MA, USA) formulated in CNS perfusion fluid (Manufacturing 
Unit, Department of Pharmacy, Ipswich Hospital NHS Trust, Ipswich, UK) for 24 hours before the MRS scan. 
Supplemented perfusion fluid was tested for purity, sterility, freedom from endotoxins and absence of pyrogenic-
ity before release for use in patients. Before, during and after succinate perfusion, microdialysis collection vials 
were analysed hourly on a bedside ISCUS analyser (M Dialysis AB); employing enzymatic colorimetric assays for 
glucose, lactate and pyruvate. The microdialysis pumps were disconnected immediately before the patients went 
into the MRI scanner, although the catheters were kept in-situ. PbtO2 monitoring probes were disconnected and 
ICP probes coiled outside the RF head coil, as described previously34.
Magnetic resonance spectroscopy. Frontal voxels supplemented with succinate were compared with 
a contralateral partner voxel in each patient. The contralateral frontal voxel was chosen as we deemed it the 
most relevant comparative volume of brain that would accommodate our 2.5 × 2.5 × 2.5 cm3 voxels. Voxels were 
inspected at time of grid positioning to ensure that they were equivalent on structural MRI sequences and free 
from significant injury. The microdialysis catheter tip (which contains gold) is seen on CT, and its position is 
also apparent on MRI. Therefore, voxel grids were positioned around patients’ catheters using their most recent 
CT scans co-registered to their MRI, then checked using susceptibility weighted MR sequences (SWI). We used 
3T Siemens (Trio and Verio) scanners with a custom 31P head-coil (PulseTeq Ltd., Chobham, UK) which has a 
birdcage design that opens to facilitate use with TBI patients requiring ventilation; measuring ATP, PCr, Pi and 
other phosphorus-containing species. Spectra (Fig. 1a,b) were acquired using oblique 2-dimensional single slice 
chemical shift imaging (2D CSI) with 2.5 × 2.5 × 2.5 cm3 voxels, flip angle 90 degrees, TR 4000 ms, TE 2.3 ms, 
and 3000 Hz band-width (exemplified by Fig. 1c – frontal succinate and comparator contralateral voxel outlined 
in yellow). Repeats were performed for 30 (19 min) or 60 (35 min) averages using weighted sampling of k-space. 
31P spectra were filtered with a 200 ms Hanning filter, fitted and peak areas computed using Siemens Syngo soft-
ware. We used the γATP, as the αATP signal is incompletely resolved from nicotine-adenine dinucleotides and 
the βATP signal (at 3 Tesla) is on the edge of the excitation pulse bandwidth transmitted by the coil. We did not 
attempt to adjust ATP values for the presence of ADP as the latter is naturally much less abundant and much of 
it MR-invisible25,35,36. Brain intracellular pH was measured by 31P MRS by chemical shift difference between PCr 
and Pi using an established equation37. Patients also received standard 1H clinical MR imaging.
Statistical analysis. In this pilot study we investigated whether substantial differences in high energy phos-
phate metabolism resulted from delivery of succinate to the brain via microdialysis catheters, based on previous 
microdialysis studies from our group (12% decrease in L/P ratio3). The difference in PCr/γATP between 31P MRS 
voxels perfused with succinate and their paired contralateral voxels was analysed using Wilcoxon signed rank test.
Microdialysis samples were defined as either being from a period of succinate supplementation, or from a 
preceding/succeeding period of baseline perfusion. The first two hours after starting or finishing succinate sup-
plementation were considered a ‘run-in period’ or ‘washout period’ and results excluded, as in our previous 
study of succinate microdialysis3. We compared the period of succinate supplementation (mean 20 hours usable 
ISCUS data and after run-in/wash out exclusion) with baseline perfusion (mean 15 hours usable ISCUS data and 
after run-in/washout exclusion) using a linear mixed effect model (‘lmer’ package in R) which considers hourly 
data points rather than period mean/medians, whilst adjusting for ‘clustering’ of data, with a random y-intercept 
(starting point) for each subject.
Correlation between percent difference in measured L/P ratio, and difference in inter-voxel PCr/γATP was 
assessed using Spearman’s correlation (‘cor.test’ function in R).
All statistical analysis was performed in R (www.r-project.org) and significance (alpha) for all tests set at 0.05.
Data availability. The datasets generated during and/or analysed during the current study are not publicly 
available for reasons of patient confidentiality, but anonymised data will be available from Prof Peter Hutchinson, 
who is the Principal Investigator of this study, on reasonable request.
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